Trials / Recruiting
RecruitingNCT06856161
A Novel Blood Test as a Biomarker in Mental Health
A Novel Blood Test as a Differential Diagnosis and Drug Efficacy Biomarker in Mental Health
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Fraser Health · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis/Schizophrenia (PSY).
Conditions
- Depression - Major Depressive Disorder
- Schizophenia Disorder
- Psychosis
- Mania (Neurotic)
- Alcohol Consumption
- Anxiety Disorder (Panic Disorder or GAD)
- Substance Use Disorders
- Alcohol Use Disorder
Timeline
- Start date
- 2025-03-25
- Primary completion
- 2027-03-15
- Completion
- 2027-08-31
- First posted
- 2025-03-04
- Last updated
- 2026-03-05
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06856161. Inclusion in this directory is not an endorsement.